Prior to the merger, St Jude was the leader in the transseptal sheaths market, whilst Abbott had developed a product, Vado, which has the potential to become a strong competitor and challenge St Jude's position.
Avant la concentration, St Jude était numéro un sur le marché des gaines transeptales, cependant qu'Abbott avait développé un produit, Vado, susceptible de devenir un concurrent sérieux et de remettre en cause la position de St Jude.